Literature DB >> 11809732

Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines.

Ruth Maron1, Anthony J Slavin, Ethan Hoffmann, Yoshinori Komagata, Howard L Weiner.   

Abstract

Oral tolerance to myelin basic protein (MBP) is an effective antigen-specific method to suppress experimental allergic encephalomyelitis (EAE). Glatiramer acetate [copolymer 1 (Cop1)] is a synthetic copolymer designed to mimic MBP which suppresses EAE, is used parenterally to treat multiple sclerosis (MS) and is being tested orally for efficacy in MS. We investigated the immunologic properties of Cop1 to determine the degree to which its effects were antigen specific using MBP TCR transgenic mice. Immunization of MBP TCR transgenic mice fed Cop1, MBP or MBP Ac1-11 resulted in decreased proliferation, and IL-2, IL-6 and IFN-gamma production, and increased secretion of IL-10 and transforming growth factor (TGF)-beta in Cop1-fed animals. IFN-gamma was decreased, and IL-10 and TGF-beta were increased in non-immunized mice fed Cop1 and stimulated in vitro with MBP. No such effects were observed in ovalbumin TCR transgenic mice. To determine if the effects of Cop1 were specific to MBP TCR-bearing cells, MBP TCR transgenic Rag2(-/-) mice were immunized and re-stimulated in vitro with Cop1. We found a marked increase in IL-4 and similar increases in IL-4 after feeding Cop1. In disease models, feeding Cop1 suppressed EAE in MBP TCR transgenic mice, (PL/J x SJL)F(1) mice, and in myelin oligodendrocyte glycoprotein-induced EAE in NOD mice. Oral Cop1 had no effect on collagen-induced arthritis. These results demonstrate that Cop1 is active orally in an antigen-specific fashion, and may function as an altered peptide ligand for MBP-specific TCR-bearing cells by decreasing pro-inflammatory cytokines (IFN-gamma) and increasing anti-inflammatory cytokines (IL-4, IL-10 and TGF-beta).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809732     DOI: 10.1093/intimm/14.2.131

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Structural insight into the role of myelin basic protein in multiple sclerosis.

Authors:  Cynthia Husted
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

2.  Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance.

Authors:  Katja Goldmann; Stephan M Ensminger; Bernd M Spriewald
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

3.  IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes.

Authors:  Divya J Mekala; Rajshekhar S Alli; Terrence L Geiger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

Review 4.  Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.

Authors:  Jeffrey A Bluestone; Hélène Bour-Jordan
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

5.  Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease.

Authors:  Qing Cai; Xiaoping Du; Bin Zhou; Chun Cai; Mohammad Habiby Kermany; Taijune Yoo
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2009-04-10       Impact factor: 1.538

6.  Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.

Authors:  Y Wang; Y Mei; S Bao; L Xu
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

7.  Immune responses to Mycobacterial heat shock protein 70 accompany self-reactivity to human BiP in rheumatoid arthritis.

Authors:  Hirofumi Shoda; Norio Hanata; Shuji Sumitomo; Tomohisa Okamura; Keishi Fujio; Kazuhiko Yamamoto
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.